Insider Buying: DENTSPLY SIRONA (NASDAQ:XRAY) Director Acquires $149,929.00 in Stock

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Michael Barber purchased 15,175 shares of the stock in a transaction dated Thursday, June 11th. The stock was purchased at an average cost of $9.88 per share, for a total transaction of $149,929.00. Following the completion of the purchase, the director directly owned 55,943 shares of the company’s stock, valued at approximately $552,716.84. The trade was a 37.22% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

DENTSPLY SIRONA Stock Performance

Shares of NASDAQ:XRAY opened at $10.03 on Thursday. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98. The business’s 50 day moving average price is $10.90 and its 200-day moving average price is $11.69. The firm has a market capitalization of $2.01 billion, a PE ratio of -3.18, a P/E/G ratio of 1.24 and a beta of 0.89. DENTSPLY SIRONA Inc. has a 1 year low of $9.40 and a 1 year high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). The firm had revenue of $880.00 million during the quarter, compared to analyst estimates of $841.80 million. DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The business’s revenue was up .1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.43 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities research analysts expect that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

XRAY has been the topic of a number of research analyst reports. Mizuho lowered their price target on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Weiss Ratings lowered DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Robert W. Baird lifted their price target on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Barclays lowered their price target on DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a research note on Thursday, June 4th. Finally, Barrington Research boosted their price objective on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a research note on Monday, March 2nd. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $13.55.

Hedge Funds Weigh In On DENTSPLY SIRONA

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Eurizon Capital SGR S.p.A. acquired a new position in DENTSPLY SIRONA during the fourth quarter worth $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in DENTSPLY SIRONA during the first quarter worth $26,000. Huntington National Bank boosted its stake in DENTSPLY SIRONA by 292.9% during the third quarter. Huntington National Bank now owns 2,786 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 2,077 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in DENTSPLY SIRONA by 337.9% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock worth $35,000 after buying an additional 2,122 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in DENTSPLY SIRONA by 119.1% during the fourth quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock worth $43,000 after buying an additional 2,051 shares during the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.